Therefore, techniques that treat Tsn-abnormalities will be crucial to take into account for immunotherapeutic efforts to target SCLC and other tumors with defects in the MHC-I antigen processing pathway (129). The gene discussed is TSN; the disease is small cell lung carcinoma.